A TNF–JNK–Axl–ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma
暂无分享,去创建一个
J. Sarkaria | S. Kesari | S. Burma | K. Hatanpaa | B. Mickey | David H. Wang | Dawen Zhao | E. Pan | A. Habib | Sonia Ali | G. Guo | K. Gong | Neha Ali | S. Shallwani
[1] S. Burma,et al. Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma , 2016, Molecular Cancer Research.
[2] M. Rudnicki,et al. Control of glioblastoma tumorigenesis by feed-forward cytokine signaling , 2016, Nature Neuroscience.
[3] K. Hatanpaa,et al. Ligand-Independent EGFR Signaling. , 2015, Cancer research.
[4] L. Recht,et al. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. , 2015, Neuro-oncology.
[5] T. Cloughesy,et al. Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma , 2015, Nature Reviews Cancer.
[6] Sourav Bandyopadhyay,et al. NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer. , 2015, Cell reports.
[7] J. Donoghue,et al. EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications , 2015, Oncogene.
[8] S. Vandenberg,et al. A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma. , 2015, Cancer research.
[9] R. Abounader,et al. Targeting MET for glioma therapy. , 2014, Neurosurgical focus.
[10] T. Pandita,et al. Constitutive and ligand-induced EGFR signaling triggers distinct and mutually exclusive downstream signaling networks , 2014, Nature Communications.
[11] S. Kesari,et al. An EGFR wild type–EGFRvIII–HB-EGF feed-forward loop regulates the activation of EGFRvIII , 2014, Oncogene.
[12] Ho-June Lee,et al. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. , 2014, Cancer cell.
[13] S. Pastorino,et al. In silico modeling predicts drug sensitivity of patient-derived cancer cells , 2014, Journal of Translational Medicine.
[14] K. Shah,et al. Multiple lesions in receptor tyrosine kinase pathway determine glioblastoma response to pan-ERBB inhibitor PF-00299804 and PI3K/mTOR dual inhibitor PF-05212384 , 2014, Cancer biology & therapy.
[15] J. Engelman,et al. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. , 2014, Cancer cell.
[16] S. Nelson,et al. Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA , 2014, Science.
[17] P. Jänne,et al. The quest to overcome resistance to EGFR-targeted therapies in cancer , 2013, Nature Medicine.
[18] G. Reifenberger,et al. EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. , 2013, Cancer cell.
[19] S. Burma,et al. Opposing effect of EGFRWT on EGFRvIII-mediated NF-κB activation with RIP1 as a cell death switch. , 2013, Cell reports.
[20] Ivan Babic,et al. De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. , 2013, Cancer discovery.
[21] D. Shaw,et al. Conformational Coupling across the Plasma Membrane in Activation of the EGF Receptor , 2013, Cell.
[22] S. Hariono,et al. Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers. , 2012, Cancer discovery.
[23] Jian Jin,et al. Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer , 2012, Cell.
[24] R. Bernards,et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.
[25] D. Housman,et al. Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation. , 2011, Cancer research.
[26] B. Halmos,et al. MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents. , 2011, Cancer research.
[27] S. Burma,et al. Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance. , 2010, Neoplasia.
[28] Yoshitaka Narita,et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. , 2010, Genes & development.
[29] S. Gabriel,et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.
[30] X. Gu,et al. Intraperitoneal injection of thalidomide attenuates bone cancer pain and decreases spinal tumor necrosis factor-α expression in a mouse model , 2010, Molecular pain.
[31] S. Toms,et al. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme , 2010, Journal of Neuro-Oncology.
[32] Forest M White,et al. Oncogenic EGFR Signaling Networks in Glioma , 2009, Science Signaling.
[33] A. Unterberg,et al. Therapeutic Inhibition of the Epidermal Growth Factor Receptor in High-Grade Gliomas: Where Do We Stand? , 2009, Molecular Cancer Research.
[34] A. Scott,et al. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. , 2009, Neoplasia.
[35] Caterina Giannini,et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] David E Levy,et al. Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. , 2008, Genes & development.
[37] Keith L. Ligon,et al. Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies , 2007, Science.
[38] H. Thaler,et al. Inhibition of Jun NH2-Terminal Kinases Suppresses the Growth of Experimental Head and Neck Squamous Cell Carcinoma , 2007, Clinical Cancer Research.
[39] Forest M White,et al. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma , 2007, Proceedings of the National Academy of Sciences.
[40] Daniel A. Haber,et al. Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.
[41] Susan M. Chang,et al. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme , 2007, Journal of Neuro-Oncology.
[42] C. James,et al. Use of an Orthotopic Xenograft Model for Assessing the Effect of Epidermal Growth Factor Receptor Amplification on Glioblastoma Radiation Response , 2006, Clinical Cancer Research.
[43] Kimmo J Hatanpaa,et al. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells. , 2006, Cancer research.
[44] Koji Yoshimoto,et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.
[45] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[46] Allan H Friedman,et al. Phase II trial of gefitinib in recurrent glioblastoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] Liang Deng,et al. Thalidomide inhibits tumor necrosis factor-alpha production and antigen presentation by Langerhans cells. , 2003, The Journal of investigative dermatology.
[48] P. Scheurich,et al. Tumor necrosis factor signaling , 2003, Cell Death and Differentiation.
[49] B. Aggarwal,et al. TNF induces internalization of the p60 receptor and shedding of the p80 receptor. , 1994, Journal of immunology.
[50] P. Humphrey,et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.